Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 6,923 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stimulation Clear all

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Interventions: Sham Intervention, Survey Administration, Transcranial Direct Current Stimulation; Procedure · Other · Device
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 60 Years to 85 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin; Drug · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 44 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Atrophic Vaginitis, Breast Cancer
Interventions: Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
Interventions: Elranatamab, Lenalidomide, Plerixafor, Melphalan, Busulfan, G-CSF, Stem cell transplant; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sarcoma
Interventions: Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), Adriamycin, Ifosfamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Treatment Resistant Depression, Epilepsy
Interventions: Device: Directional Deep Brain Stimulation; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 22 Years to 70 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Normal Physiology
Interventions: TMS; Device
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
Interventions: Fludarabine, Melphalan, Alemtuzumab, Stem Cell Infusion, Tacrolimus, Methotrexate, G-CSF, Low Dose Donor T-Cells, High Dose Donor T-Cells; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Postoperative Pain
Interventions: perineural mepivicaine catheter placed via ultrasound or electrical stimulation; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Essential Tremor, Parkinson's Disease
Interventions: Encora Pulse; Device
Lead sponsor: Encora, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Primary Progressive Aphasia
Interventions: Transcranial Direct Current Stimulation (tDCS), Sham tDCS, Modified Contraint-Induced Language Therapy (mCILT); Device · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 45 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Neoplasm
Interventions: Cladribine, Cytarabine, Granulocyte Colony-Stimulating Factor, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration; Drug · Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Schizophrenia, Schizo Affective Disorder
Interventions: tDCS; Device
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Lymphoma
Interventions: darbepoetin alfa, filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan; Biological · Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years to 120 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2019
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Urinary Incontinence, Urge
Interventions: CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System; Device
Lead sponsor: Uro Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 15
States / cities: Laguna Hills, California • Los Angeles, California • Orange, California + 12 more

Conditions: Depression - Major Depressive Disorder
Interventions: transcutaneous spinal direct current stimulation; Device
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 60 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder I
Interventions: Excitatory TMS, Inhibitory TMS, Sham TMS; Device
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Belmont, Massachusetts • Charlestown, Massachusetts

Conditions: Fanconi Anemia
Interventions: Anti-Thymocyte Globulin, Cyclophosphamide, Fludarabine, Hematopoietic Stem Cell Transplantation, Methylprednisolone, Filgrastim, Cyclosporine, Mycophenolate Mofetil; Biological · Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 59 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Spinal Cord Injury, Tetraplegia
Interventions: transcranial direct current stimulation, peripheral nerve somatosensory stimulation, sham transcranial direct current stimulation; Other
Lead sponsor: Shepherd Center, Atlanta GA; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Childhood Stroke
Interventions: Transcranial Direct Current Stimulation (tDCS); Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 5 Years to 19 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Total Knee Arthroplasty
Interventions: CyMedica e-vive™ System; CY-1000, iGetBetter telemedicine physical therapy; Device · Other
Lead sponsor: Wolfgang Fitz, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bladder Injury
Interventions: Obturator nerve block; Procedure
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 35 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Demyelinating Disease, Healthy, Lysosomal Storage Disease, Motor Neuron Disease, Movement Disorder
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Transcranial Direct Current Stimulation to Improve Gait for Breast Cancer Survivor's Who Received Taxene and/or Platinum Chemotherapy

Busulfan and Cyclophosphamide Followed By ALLO BMT

Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing

Task-dependent Effects of TMS on the Neural Biomarkers of Episodic Memory

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Ultrasound Guidance Versus Electrical Stimulation for Perineural Catheter Insertion

Home Use Study of Targeted Mechanical Stimulation for Tremor Relief

Treating Primary Progressive Aphasia (PPA) Using tDCS

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

The Efficacy of Neural Stimulation in Individuals With Schizophrenia

Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology

Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains

Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study

Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia

Conditioning Neural Circuits to Improve Upper Extremity Function

TOlerability of Transcranial Direct Current Stimulation in Pediatric Stroke Survivors

Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer

Is There an Alternative to Immediate Home Physical Therapy Following Total Knee Arthroplasty

Preventing the Obturator Nerve Reflex

Magnetic Stimulation of the Human Nervous System